GlassScriptPhysician profile
Salah E El Hafi
NPI 1396969622
$5,099.66
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,058 · 2020: $41.78.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $3,545.36 | 2019-2020 | |
| Astellas Pharma US INC | $268.39 | 2019 | |
| Janssen Pharmaceuticals, INC | $184.62 | 2019-2020 | |
| Amgen INC. | $166.63 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $149.33 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $140.78 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.92 | 2019 | |
| Sanofi-Aventis U.S. LLC | $101.48 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $67.17 | 2019 | |
| Amarin Pharma, INC. | $60.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $54.03 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $53.69 | 2019 | |
| Boston Scientific Corporation | $51.61 | 2019 | |
| Pfizer INC. | $34.63 | 2019 | |
| Arbor Pharmaceuticals, INC. | $30.58 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $30.39 | 2019 | |
| Gilead Sciences, INC. | $19.18 | 2019 | |
| Irhythm Technologies, INC. | $11.34 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salah El Hafi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.